Telik, Inc. (Telik) is a clinical-stage drug development company focused on discovering and developing small molecule drugs to treat cancer. The Company discovers its product candidates using the Company�s drug discovery technology, Target-Related Affinity Profiling (TRAP). TELINTRA, its principal drug product candidate in clinical development, is a small molecule glutathione analog inhibitor of the enzyme glutathione S-transferase P1-1 (GST P1-1). TELCYTA, its other product candidate, is a small molecule cancer drug product candidate designed to be activated in cancer cells. In July 2014, Telik Inc announced that MabVax Therapeutics merged with a wholly owned subsidiary of Telik Inc and became a wholly owned subsidiary of Telik Inc.